TSHA (Taysha Corp) Operating Margin

Public company logo of Taysha (TSHA)

The operating profit margin reflects the impact of positive data regarding Rett syndrome therapy, with the -2998.00 mark serving as the current indicator. Taysha Gene Therapies (TSHA) ensures business efficiency through a management restructuring focused on a single key drug. The competitiveness of Taysha Gene Therapies (TSHA) is based on targeted gene delivery systems and tax preferences for orphan drugs, which guarantees a temporary monopoly in the treatment of nervous system pathologies.

TSHA: Taysha Gene Therapies, Inc. Operating Return on Sales 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company tayshagtx.com (TSHA)

Summary company analytics:Taysha Corp, TSHA
Finished products of Taysha Gene Therapies

Protecting capital from market volatility requires a deep understanding of a business's internal efficiency. The partnership of Taysha Gene Therapies (TSHA) with pediatric clinics treating rare CNS pathologies forms the foundation for future monetization. By analyzing the EBIT margin, an investor assesses the share of operating profit in revenue before financial expenses. This indicator measures the company's ability to generate cash flow from its core operations. The stability of this metric determines the long-term resilience of the portfolio.

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability